MGNX

Macrogenics Inc

• TipRanks·25m ago

  MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study

• Reuters·30m ago

  FDA lifts partial hold on MacroGenics lorigerlimab Phase 2 LINNET trial

• Benzinga·31m ago

  MacroGenics Says FDA Removes Partial Clinical Hold On Phase 2 LINNET Study Of Lorigerlimab, Investigational, Bispecific DART Molecule That Targets PD-1 And CTLA-4

• Reuters·33m ago

  MACROGENICS INC - PLAN TO RESUME ENROLLMENT IN CLINICAL STUDY OF LORIGERLIMAB IN GYNECOLOGIC CANCERS

• TipRanks·03/11 13:16

  Stifel Nicolaus Sticks to Its Hold Rating for MacroGenics (MGNX)

• NASDAQ·03/11 10:44

  MacroGenics Reaches Analyst Target Price

• Simply Wall St·03/11 03:24

  MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative

• Benzinga·03/10 17:06

  12 Health Care Stocks Moving In Tuesday's Intraday Session

• Dow Jones·03/10 14:27

  Macrogenics Price Target Raised to $4.00/Share From $3.00 by Barclays

• Dow Jones·03/10 14:27

  Macrogenics Is Maintained at Overweight by Barclays

• Benzinga·03/10 14:17

  Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

• Reuters·03/10 10:38

  MACROGENICS <MGNX.O>: BARCLAYS RAISES TARGET PRICE TO $4 FROM $3

• TipRanks·03/10 09:26

  Barclays Sticks to Their Buy Rating for MacroGenics (MGNX)

• Reuters·03/10 07:23

  U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx

• TipRanks·03/09 22:30

  Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC)